Ribotype 027 Clostridium difficile infections with measurable stool toxin have increased lactoferrin and are associated with a higher mortality

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 33, Issue 6, 2014, Pages 1045-1051

  Boone, J H ^a   Archbald Pannone, L R ^b   Wickham, K N ^a   Carman, R J ^a   Guerrant, R L ^b   Franck, C T ^c   Lyerly, D M ^a  

^a TECHLAB INC   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CLOSTRIDIUM DIFFICILE TOXIN B; CREATININE; LACTOFERRIN; BACTERIAL TOXIN; LTF PROTEIN, HUMAN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BACTERIUM CULTURE; CHARLSON COMORBIDITY INDEX; CLOSTRIDIUM DIFFICILE INFECTION; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FECES; FEMALE; HOSPITAL PATIENT; HUMAN; HUMAN TISSUE; INTENSIVE CARE UNIT; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RIBOTYPING; TISSUE CULTURE; UNIVARIATE ANALYSIS; CHEMISTRY; CLASSIFICATION; CLOSTRIDIUM INFECTION; COHORT ANALYSIS; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; SURVIVAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COHORT STUDIES; FECES; FEMALE; HUMANS; LACTOFERRIN; MALE; MIDDLE AGED; RIBOTYPING; SURVIVAL ANALYSIS;

EID: 84903816556     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-013-2043-1     Document Type: Article

References (48)

1. Redelings MD, Sorvillo F, Mascola L (2007) Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis 13(9):1417-1419 (Pubitemid 47510317)
2. Goorhuis A, Debast SB, Dutilh JC, van Kinschot CM, Harmanus C, Cannegieter SC et al (2011) Type-Specific risk factors and outcomes in an outbreak with 2 different Clostridium difficile types simultaneously in 1 hospital. Clin Infect Dis 53(9):860-869
3. Hensgens MP, Goorhuis A, Dekkers OM, van Benthem BH, Kuijper EJ (2013) All-cause and disease-specific mortality in hospitalized patients with Clostridium difficile infection: a multicenter cohort study. Clin Infect Dis 56(8):1108-1116
4. Hubert B, Loo VG, Bourgault AM, Poirier L, Dascal A, Fortin E et al (2007) A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Quebec. Clin Infect Dis 44:237-244
5. Labbe A, Poirier L, MacCannell D, Louie T, Savoie M, Beliveau C, Laverdiere M, Pepin J (2008) Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. Agents Chemother 52(9):3180-3187
6. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S et al (2005) A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353:2442-2449 (Pubitemid 41770165)
7. Morgan OW, Rodrigues B, Elston T, Verlnader NQ, Brown DF, Brazier J et al (2008) Clinical severity of Clostridium difficile PCR ribotype 027: a case-case study. PLoS One 3:1-6
8. Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, Posey K et al (2005) A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 26(3):273-280 (Pubitemid 40445086)
9. Pepin J, Saheb N, Coulombe M, Alary M, Corriveau M, Authier S et al (2005) Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: A cohort study during an epidemic in Quebec. Clin Infect Dis 41:1254-1260 (Pubitemid 41532667)
10. Carlson PE, Walk ST, Bourgis AE, Liu M, Kopliku F, Lo E (2013) The relationship between phenotype, ribotype, and clinical disease in human Clostridium difficile isolates. Anaerobe 24:109-116
11. Merrigan M, Venugopal A, Mallozzi M, Roxas B, Viswanathan VK, Johnson S et al (2010) Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J Bacteriol 192(19):4904-4911
12. Moore P, Kyne L, Martin A, Solomon K (2013) Germination efficiency of clinical Clostridium difficile spores and correlation with ribotype, disease severity and therapy failure. J Med Microbiol 62(Pt 9):1405-1413
13. O'Connor JR, Johnson S, Gerding D (2009) Clostridium difficile infection caused by epidemic BI/NAP1/027 Strain. Gastroenterology 136:1913-1924
14. Vohra P, Poxton IR (2011) Comparison of toxin and spore production in clinically relevant strains of Clostridium difficile. Microbiology 157:1343-1353
15. Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J et al (2005) Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366(9491):1079-1084 (Pubitemid 41338761)
16. Barbut F, Rupnik M (2012) 027, 078 and others: going beyond the numbers (and away from the hypervirulence). Clin Infect Dis 55(12):1669-1672
17. Cloud J, Noddin L, Pressman A, Hu M, Kelly C (2009) Clostridium difficile strain NAP-1 is not associated with severe disease in a nonepidemic setting. Clin Gastro and Hep 7:868-873
18. Gerding D, Johnson S (2013) Does infection with specific Clostridium difficile strains or clades influence clinical outcome? Clin Infect Dis 56(11):1601-1603
19. Sirard S, Valiquette L, Fortier L (2011) Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes. J Clin Microbiol 49(12):4040-4046
20. Walk ST, Micic D, Jain R, Lo ES, Trivedi I, Liu EW et al (2012) Clostridium difficile ribotype does not predict severe infection. Clin Infect Dis 55(12):1661-1668
21. Burnham CD, Carroll KC (2013) Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories. Clin Micro Rev 26(3):604-630
22. Crobach MJ, Dekkers OM, Wilcox MH, Kuijper EJ (2009) European Society of Clinical Microbiology and Infectious Diseases (ESCMID): Data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect 15:1053-1066
23. Planche TD, Davies KA, Coen PG, Finney JM, Monohan IM, Morris KA et al (2013) Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C. difficile infection. Lancet Infect Dis 13(11):936-945
24. Polage CR, Chin DL, Leslie JL, Tang J, Cohen SH, Solnick JV (2012) Outcomes in patients tested for Clostridium difficile toxins. Diagn Microbiol Infect Dis 74(4):369-373
25. Bhangu A, Czapran A, Bhangu S, Pillay D (2010) Optimum timing of blood tests for monitoring patients with Clostridium difficile-associated diarrhea. J Investig Med 58(4):621-624
26. Bloomfield MG, Sherwin JC, Gkrania-Klotsas E (2012) Risk factors for mortality in Clostridium difficile infection in the general hospital population: a systematic review. J Hosp Infect 82:1-12
27. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC et al (2010) Clinical Practice Guidelines for Clostridium difficile Infection: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 31(5):431-455
28. Fujitani S, George WL, Murthy AR (2011) Comparison of clinical severity score indices for Clostridium difficile infection. Infect Control Hosp Epidemiol 32(3):220-228
29. Henrich TJ, Krakower D, Bitton A, Yokoe DS (2009) Clinical risk factors for severe Clostridium difficile-associated disease. Emerg Infect Dis 15(3):415-422
30. Pant C, Madonia P, Minocha A, Manas K, Jordan P, Bass P (2009) Laboratory markers as predictors of mortality in patients with Clostridium difficile infection. J Investig Med 57(8):1-3
31. Surawicz CM, Brandt L, Binion DG, Ananthakrishnan AN, Curry SR, Gilligin PH et al (2013) Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infection. Am J Gastroenterol 108:478-498
32. Walker AS, Eyre DW, Wyllie DH, Dingle KE, Griffiths D, Shine B et al (2013) Relationship between bacterial strain type, host biomarkers and mortality in Clostridium difficile infection. Clin Infect Dis 56(11):1589-1600
33. Guerrant RL, Araujo V, Soares E, Kotloff K, Lima A, Cooper W, Lee A (1992) A measurement of fecal lactoferrin as a marker of fecal leukocytes. J Clin Microbiol 30:1238-1242
34. Pawlowski SW, Archbald-Pannone L, Carman RJ, Alcantara-Warren C, Lyerly D, Genheimer CW et al (2009) Elevated levels of intestinal inflammation in Clostridium difficile infection associated with fluoroquinolone-resistant C. difficile. J Hosp Infect 73(2):185-187
35. Schleupner MA, Garner DC, Sosnowski KM, Scheulpner CJ, Barrett LJ, Silva DH et al (1995) Concurrence of Clostridium difficile toxin A enzyme-linked immunosorbent assay, fecal lactoferrin assay, and clinical criteria with cytotoxin titer in two patient cohorts. J Clin Microbiol 33:1755-1759
36. Wren MW, Sivapalan M, Kinson R, Shetty NR (2009) Laboratory diagnosis of Clostridium difficile infection. An evaluation of tests for faecal toxin, glutamate dehydrogenase, lactoferrin and toxigenic culture in the diagnostic laboratory. Br J Biomed Sci 66(1):1-5
37. Boone JH, DiPersio JR, Tan MJ, Salstrom S-J, Wickham KN, Carman RJ et al (2013) Elevated lactoferrin is associated with moderate to severe Clostridium difficile disease, stool toxin, and 027 infection. Eur J Clin Microbiol Infect Dis. doi:10.1007/s10096-013-1905-x
38. Feghaly RE, Stauber JL, Deych E, Gonzalez C, Tarr P, Haslam D (2013) Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection. Clin Infect Dis 56(12):1713-1721
39. LaSala PR, Ekhmimi T, Hill AK, Farooqi I, Perrotta PL (2013) Quantitative fecal lactoferrin in toxin-positive and toxin-negative Clostridium difficile specimens. J Clin Microbiol 51(1):311 - 313
40. Yacyshyn MB, Yacyshyn B (2013) The role of gut inflammation in recurrent CDAD. Clin Infect Dis 56(12):1722-1730
41. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1986) A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chron Dis 40(5):373-383 (Pubitemid 17055592)
42. Drekonja DM, Rector TS, Cutting A, Johnson JR (2013) Urinary tract infection in male veterans: treatment patterns and outcomes. JAMA Intern Med 173(1):62-68
43. Boone JH, Goodykoontz M, Rhodes SJ, Price K, Smith J, Gearhart KN et al (2012) Clostridium difficile prevalence rates in a large healthcare system stratified according to patient population, age, gender, and specimen consistency. Eur J Clin Microbiol Infect Dis 31(7):1551-1559
44. Stubbs SL, Brazier JS, O'Neill GL, Duerden BI (1999) PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 37:461-463 (Pubitemid 29056430)
45. Akerlund T, Svenungsson B, Lagergren A, Burman L (2006) Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotype and toxin yields in vitro of corresponding isolates. J Clin Microbiol 44(2):353-358 (Pubitemid 43222222)
46. Baker I, Leeming JP, Reynolds R, Ibrahim I, Darley E (2013) Clinical relevance of a positive molecular test in the diagnosis of Clostridium difficile infection. J Hosp Infect 4(4):311-315
47. Kuehne S, Collery M, Kelly M, Cartman S, Cockayne A, Menton N (2014) The importance of toxin A, toxin B and CDT in virulence of an epidemic Clostridium difficile strain. J Infect Dis 209(1):83-86
48. Koon HW, Shih DQ, Hing TC, Yoo JH, Ho S, Chen X et al (2013) Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytes. Antimicrobiol Agents Chemother 57(7):3214-3223